Lonza Group publishes restated 2025 half-year figures, shares in focus on SIX

Lonza Group has released restated half-year 2025 financials to reflect Capsules & Health Ingredients as discontinued operations and remains active on the M&A front with a licensing deal for next?generation ADCs. The Swiss mid-cap stays in focus for SIX investors.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 07:07.

Lonza Group AG (CH0013841017) has published restated half-year 2025 figures to treat its Capsules & Health Ingredients activities as discontinued operations, according to an ad-hoc statement released via EQS on 23 June 2026 and reflected on SIX Swiss Exchange.

What the restatement changes

In the EQS announcement, Lonza explains that the half-year 2025 financial statements have been retroactively adjusted so that the Capsules & Health Ingredients business is now presented under discontinued operations, aligning reporting with the strategic divestment of that unit completed earlier. The EQS ad-hoc release on the restated half-year 2025 figures states that the restatement affects income statement, cash flow statement and selected notes for the comparative period.

By reclassifying Capsules & Health Ingredients, Lonza cleans up its continuing-operations baseline in Bioscience and Biologics, which is particularly relevant for analysts who compare margins against European CDMO peers like Sartorius and Siegfried in the healthcare and life sciences sector.

Analysts and sector context on Tuesday

The refocused reporting comes as Lonza remains part of the Swiss Performance Index (SPI), where healthcare-exposed names such as Roche and Novartis set the tone for many international investors tracking Swiss large and mid caps. Consensus data aggregated by MarketScreener earlier in June shows a mixed analyst stance on Lonza, with a broad split between Buy and Hold ratings and a wide range of price targets reflecting differing views on the CDMO investment cycle. The MarketScreener consensus page on Lonza lists multiple active broker opinions, including contributions from UBS and other European banks.

In addition to the restatement, Lonza recently announced a licensing agreement with US-based InduPro for next-generation antibody-drug conjugates (ADCs), underlining its strategic focus on complex biologics and oncology-related technologies within the broader CDMO sphere. A Reuters market report on the InduPro licensing deal highlighted that the collaboration targets innovative ADC formats intended to improve therapeutic windows in cancer treatment.

How Lonza makes its money

Lonza’s core business centers on contract development and manufacturing for the biopharmaceutical industry, with offerings that span mammalian and microbial biologics, cell and gene therapies and sterile fill-and-finish services for global pharma and biotech clients.

Where the stock trades today

The Lonza Group AG shares (CH0013841017) last traded on SIX Swiss Exchange at 538.00 Swiss francs on 2026-06-23, 09:30.

Key data on the Lonza Group AG shares

• Company: Lonza Group AG
• ISIN: CH0013841017
• WKN: 928619
• Ticker: LONN
• Trading venue: SIX Swiss Exchange
• Price (as of 2026-06-23, 09:30): 538.00 CHF
• Market cap: 40.5 billion CHF (as of 2026-06-23)
• Sector / industry: Healthcare - Life Sciences Tools & Services / CDMO
• Index membership: SPI, SMIM
• Next earnings date: 2026-07-25

This article is for informational purposes only and does not constitute investment advice, an offer or a solicitation to buy or sell any securities.